Literature DB >> 29668538

Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience.

Daniel C Moreira1, Margaret E Macy, Carrye R Cost, Brian S Greffe, Timothy P Garrington.   

Abstract

The incidence of central nervous system (CNS) involvement in patients with rhabdomyosarcoma (RMS) is low, and the outcome is dismal. We present a single institution analysis of CNS involvement of pediatric RMS. In 59 patients, the prevalence of CNS involvement was 11.9% (7 patients), higher than prior reports. Of the 6 deaths from disease, all had rapid progression, with a median survival of 14 days. The higher incidence could be secondary to treatment modifications or more sensitive detection. These findings are useful for decisions at the time of CNS involvement and could lead to modifications for future RMS clinical trials.

Entities:  

Mesh:

Year:  2019        PMID: 29668538      PMCID: PMC6192856          DOI: 10.1097/MPH.0000000000001166

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  19 in total

Review 1.  Pharmacology of agents used in bone marrow transplant conditioning regimens.

Authors:  V J Wiebe; B R Smith; M W DeGregorio; J M Rappeport
Journal:  Crit Rev Oncol Hematol       Date:  1992-11       Impact factor: 6.312

2.  Pharmacokinetics of actinoymcin D in patients with malignant melanoma.

Authors:  M H Tattersall; J E Sodergren; S K Dengupta; D H Trites; E J Modest; E Frei
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

Review 3.  Brain metastasis in pediatric extracranial solid tumors: survey and literature review.

Authors:  Rejin Kebudi; Inci Ayan; Omer Görgün; Fulya Yaman Ağaoğlu; Sema Vural; Emin Darendeliler
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.

Authors:  Aaron C Spalding; Douglas S Hawkins; Sarah S Donaldson; James R Anderson; Elizabeth Lyden; Fran Laurie; Suzanne L Wolden; Carola A S Arndt; Jeff M Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

5.  Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010.

Authors:  Rebecca Smith-Bindman; Diana L Miglioretti; Eric Johnson; Choonsik Lee; Heather Spencer Feigelson; Michael Flynn; Robert T Greenlee; Randell L Kruger; Mark C Hornbrook; Douglas Roblin; Leif I Solberg; Nicholas Vanneman; Sheila Weinmann; Andrew E Williams
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

6.  Pathology of fatal rhabdomyosarcoma. Report from Intergroup Rhabdomyosarcoma Study (IRS-I and IRS-II).

Authors:  H Shimada; W A Newton; E H Soule; M S Beltangady; H M Maurer
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

7.  Brain metastases in children.

Authors:  F Graus; R W Walker; J C Allen
Journal:  J Pediatr       Date:  1983-10       Impact factor: 4.406

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

10.  Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain.

Authors:  Iacopo Sardi; Giancarlo la Marca; Stefania Cardellicchio; Laura Giunti; Sabrina Malvagia; Lorenzo Genitori; Maura Massimino; Maurizio de Martino; Maria G Giovannini
Journal:  Am J Cancer Res       Date:  2013-08-14       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.